Needle Free Injection System Market

Global Needle-Free Injection System Market Size (2023 to 2028)

The global needle-free injection system market size is anticipated to grow with a CAGR of 16.3% from 2023 to 2028 and will be worth USD 26.95 Billion by 2028 from USD 18.51 billion in 2023.

Needle-Free injections are tools used without scratching the skin with a traditional needle to deliver fluid medications, medicines, and vaccines. Since these systems enhance the immune response to vaccines, minimize needle threats, and raise healthcare costs, increasing demand has been seen in these systems' demands. Needle-free techniques deliver a very apparent advantage in patients to minimize needle phobia. In the past few years, the number of patients utilizing self-administered drugs has increased significantly. Also, the Disease Control and Prevention Centers and Division of Diabetes Translation (DDT) support state and local health agencies in promoting initiatives and programs aimed at reducing or preventing diabetes mellitus and improving the health outcomes of patients with diabetes.

MARKET DYNAMICS:

Rising chronic disease prevalence, increased incidence of contagious disease due to needle stick injuries, increased demand for biosimilars and immunization, benefits of drug delivery technology, and increased demand for self-injection devices are key factors driving the global needle-free injection system market growth. For example, the disposable Syringe Jet Injector Project favors clinical research studies using jet injectors to supply vaccines. As a result, the rising demand for biosimilars and vaccination will increase the need for this device.

It is possible to configure needle-free injectors as needed and they can be adjusted to maximize their productivity. Nevertheless, it may be challenging to implement a Needle-Free injection system. Also, high training costs and high needle-free injector production costs over traditional needle injection could hamper the global needle-free injection system market growth in the years ahead.

The needle-free injection technique removes the risks of skin puncture or bleeding and swelling issues. Associations such as WHO and CDC, the Centre for Disease Control, and organizations such as the Gates Foundation serve the needs of needle-free drug delivery options that will create enormous future growth opportunities.

Impact of COVID-19 on the global needle-free injection system market:

The coronavirus outbreak (COVID-19) has affected millions of people keeping lives at risk and every business sector, including healthcare. The eruption has spread to almost every corner of the world. The various governments had imposed the lockdowns following strict guidelines to avoid spreading the virus. Patients have stopped visiting the clinics and hospitals during the lockdown, and all the doors remained temporarily closed during the pandemic. The outbreak has impacted the needle-free injection system and continues to do the same. The creative maker of needle-free injections PharmaJet, disclosed its Stratis Needle-free injection used for delivering vaccines against COVID-19 in clinical trials in Australia. COVIDIEN is a DNA-based vaccine advanced by French-Thai Pharma Company BioNet and Melbourne-based biotech Technovalia. The phase 1 trial is a collaboration. The PharmaJet's needle-free injection delivers messenger RNA (mRNA) vaccine in opposition to SARA-CoV-2. Abnova Corporation enhanced the vaccine comprising of new adjuvant increasing the efficiency of the mRNA patient. Abnova Corporation is the world's most significant antibody producer in Taiwan, China. 

REPORT COVERAGE:

This research report on the global needle-free injection system market has been segmented and sub-segmented based on the product, power source, usability, type, delivery site, application, end-user, and region.

Needle-Free Injection System Market - By Product:

• Fillable
• Prefilled

Based on the product, the prefilled needle-free injection system segment is projected to grow at a significant CAGR during the forecast period. The acceleration in the incidence rate of chronic diseases such as diabetes needs an appropriate portion to be controlled by the patient is one of the factors primarily driving the growth of this segment.

Simultaneously, the fillable product segment will perform well during the forecast timeline.

Needle-Free Injection System Market - By Source of Power:

• Spring-based Injector Systems
• Gas-Propelled/Air Forced Injector Systems

Based on the power source, the air-forced injector systems segment is expected to lead the market, accounting for the highest market share during the forecast period. Benefits associated with the air-forced-injected systems, such as quick drug delivery and better replicability resulting in improved availability, are majorly propelling the growth of this segment.

Needle-Free Injection System Market - By Type:

• Liquid-based
• Projectile/Depot-based
• Powder-based

Based on type, the liquid-based needle-free injection system is anticipated to grow fastest during the forecast period. The burgeoning demand for biologics and advanced technologies accentuates the market growth. As a result, the liquid-based type segment is another lucrative segment.

Needle-Free Injection System Market - By Usability:

• Disposable
• Reusable

Based on usability, the reusable usability segment is forecasted to witness healthy growth during the forecast period.

Needle-Free Injection System Market - By Site of Delivery:

• Subcutaneous Injectors
• Intramuscular Injectors
• Intradermal Injectors

Based on the delivery site, the subcutaneous injectors segment is projected to dominate the market due to the growing importance of patients towards the self-administration of drugs.

Needle-Free Injection System Market - By Application:

• Vaccine Delivery
• Insulin Delivery
• Pain Management
• Others

Based on application, Insulin delivery is the most prominent application segment in the needle-free drug delivery device market. Growth in this segment appears to be an increase in the incidence of diabetes and a shift to an unhealthy lifestyle. For example, according to the Centers for Disease Control and Prevention, about 30.3 million people worldwide had diabetes in 2017, of which 9.4% were U.S. citizens. However, approximately 23.1 million have been diagnosed, and 7.2 million have not.

With the introduction of technologically advanced products such as micro insulin pumps, insulin pens, insulin sprays, respirable insulin, and other new jet injectors, the field of insulin delivery is expected to achieve significant CAGR within the forecast period. 

Needle-Free Injection System Market - By End User:

• Hospitals & Clinics
• Home Care Settings
• Research Laboratories
• Others

Based on the end-user, the hospitals and clinics segment is expected to be the leading segment during the forecast period. With an escalating patient count and an increasing number of older people, the rising number of chronic diseases will likely propel the market growth. Moreover, the medicine development and advancements in drug delivery, expanding healthcare expenses, and sound knowledge on health and wellness, upsurge the market growth.

Needle-Free Injection System Market - By Region

• North America
  • The U.S.
  • Canada
  • Rest of North America
• Europe
  • UK
  • France
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• APAC
  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Rest of APAC
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Chile
  • Rest of Latin America
• Middle East
• Africa

In the last few years, North America has dominated the global needle-free injection system market, with a significant share held by the United States. Nevertheless, Europe is expected to grow at the highest CAGR in the forecast period. The robust growth in this market is due to the increasing demand for biologics, the rising prevalence of chronic conditions, technological advances, mergers and acquisitions by major market players, favorable reimbursement policies, increased healthcare spending, and authorizations of the new injection system are key factors driving the growth of the European Needle Free Injection System Market.

Asia-Pacific offers lucrative business opportunities to grow due to the high population base and increased awareness of the advantages of Needle-Free injections and their use in cancer and diabetes care. However, Japan is projected to see the fastest growth throughout the forecast period due to patients ' propensity towards advanced technology, increased demand for biologics, and increased healthcare spending. 

KEY MARKET PLAYERS:

Some of the significant participants dominating the global needle-free injection system market profiled in this report are Akra Dermojet, Antares Pharma, Becton Dickinson and Company, Bioject Medical Technologies, Crossject, Endo International, European Pharma Group, Glide Pharma Technologies, INJEX Pharma, Inovio Pharmaceuticals, Lundbeck, Medical International Technology, MedImmune, Mystic Pharmaceuticals, National Medical Products, Optinose, PenJet Corporation, PharmaJet, Powderject Pharmaceuticals, PowderMed, Valeritas, Weston medical and Zogenix

RECENT MARKET HAPPENINGS:

• In 2019, Novartis launched EpiPen at about $ 250.0, cheaper than other EpiPen products on the market.
• The global needle-free injection system market could also benefit from the organic growth of the healthcare industry. It is due to modern treatment strategies and pharmaceutical advances. In addition, increased demand for biologics, favorable reimbursement policies, increased healthcare costs, and mergers and acquisitions by key players could drive the global needleless injection system market.
• Regarding strategic development, the needle-free injection system market has received various new product releases and approvals. In March 2017, PharmaJet, in collaboration with the Serum Institute of India, announced the commercialization of the needleless measles, mumps, and rubella (MMR) vaccine using the Stratis 0.5 mL needle-free injection system.
• Increasing cooperation among market participants may further enhance the competitiveness of this market. For example, PharmaJet and Mundipharma partnered in 2018 to sell needle-free syringes in 120 markets worldwide. Also, Portal Instruments cooperate and use Takeda's biopharmaceuticals together. These initiatives are expected to lead the market over the forecast period, and Crossject's Zeneno is likely to be launched in the coming years with lower anticipated prices.